Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 12/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.48 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18694794 | 0.90 | KDM4E (0.51) | CFTRCCNE1CDK2KDM4EHPGD | |
| SCHEMBL18694424 | 0.84 | CFTR (0.55) | CFTRKDM4EHPGDHSD17B10MAPT | |
| SCHEMBL18694812 | 0.83 | CFTR (0.52) | CFTRCCNE1CDK2CDK1CCNB1 | |
| SCHEMBL18694571 | 0.79 | CFTR (0.73) | CFTR | |
| SCHEMBL18694232 | 0.75 | KDM4E (0.59) | CFTRKDM4EHPGDHSD17B10MAPT | |
| SCHEMBL18743336 | 0.75 | KDM4E (0.58) | CFTRKDM4EHPGDHSD17B10MAPT | |
| SCHEMBL18694494 | 0.74 | KDM4E (0.47) | CFTRCCNE1CDK2KDM4EHPGD | |
| SCHEMBL18694144 | 0.73 | KHK (0.56) | CFTRKDM4EHPGDHSD17B10MAPT | |
| SCHEMBL18694396 | 0.73 | HPGD (0.60) | KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL18693874 | 0.72 | CFTR (0.63) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | claimed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | claimed |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | ABBVIE S.Á.R.L. (LU) | 2018-11-20 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | CFTR 1/4885CCNE1 2152/4885CDK2 1587/4885 |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | CFTR, CLCN2, SLC26A4 | CFTR 1/4885CCNE1 3257/4885CDK2 4018/4885 |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SLC26A4 | CFTR 1/4885CCNE1 3530/4885CDK2 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.